2025 Europe Automation In Biopharmaceutical Market Revenue Opportunities Report
Description
The 2025 Europe Automation In Biopharmaceutical Market Revenue Opportunities Report features 1) market size data for the region or country, 2) annual market growth rates, 3) the market's impact on related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing, 4) Total Addressable Market (TOM) for the four largest market players, 5) Serviceable Addressable Market (SAM), and 6) Serviceable Obtainable Market (SOM)(Wharry Sharpe Research)
The Revenue Opportunities Reports provide market size data for a three-year historical trend (2019-2022), a three-year forecast estimate trends (2023-2025), and a five-year outlook projection (2026-2031) for the region or country. The report also features written analysis on market definitions, and market segments.
Market and product shipments include the total value of all products produced and shipped by all producers (also described as value of receipts, value of production, or value of work done.)
The report features written analysis and market size statistics on opportunities created in the Automation in Biopharmaceutical Market by the changing related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing,
The four largest companies actively participating in automation within the biopharmaceutical market in Europe include GlaxoSmithKline (GSK), AstraZeneca, Harro Hoefliger, and ESSERT Robotics. GSK and AstraZeneca, both based in the UK, are leading pharmaceutical firms extensively integrating AI and automation technologies to accelerate drug discovery, development, and manufacturing processes, with GSK having established an AI hub in London for new drug discovery. Harro Hoefliger, a German company, specializes in flexible automation solutions for pharmaceutical production and packaging, offering machines for capsule, tablet, powder, and inhalation products and assembly carton packaging. ESSERT Robotics focuses on high-mix, low-volume automation, creating modular production lines tailored for pharmaceutical manufacturing and laboratory automation, emphasizing flexibility and variability in production output.
These companies leverage advancements such as AI-driven predictive maintenance, robotics, and digital transformation to enhance efficiency and maintain compliance in complex biopharma manufacturing environments. European pharmaceutical manufacturers, including these key players, are investing heavily in cybersecurity, AI, and physical automation to overcome challenges like data silos and regulatory audits. The increasing adoption of AI-powered virtual assistants and automation technologies optimizes operations, improving equipment effectiveness and productivity in the pharmaceutical supply chain across Europe. This collective innovation drives the growth and competitiveness of the biopharmaceutical automation market within the region.
Revenue Opportunities are defined by the measurements of Total Addressable Market (TOM) for the four largest market players, Serviceable Addressable Market (SAM), and Serviceable Obtainable Market (SOM). The measurements include both written analysis and current calculations for each company in the market for each country or region.
This report does not provide the names of companies in the market or written analysis of each market's trends within each country to provide a cost-effective report that focuses solely on the statistics and data on each market.
Wharry Sharpe Research publishes thousands of market analysis and product research report annually to assist their clients with the essential data they need for the market research, budgeting and forecasting needs.
The Revenue Opportunities Reports provide market size data for a three-year historical trend (2019-2022), a three-year forecast estimate trends (2023-2025), and a five-year outlook projection (2026-2031) for the region or country. The report also features written analysis on market definitions, and market segments.
Market and product shipments include the total value of all products produced and shipped by all producers (also described as value of receipts, value of production, or value of work done.)
The report features written analysis and market size statistics on opportunities created in the Automation in Biopharmaceutical Market by the changing related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing,
The four largest companies actively participating in automation within the biopharmaceutical market in Europe include GlaxoSmithKline (GSK), AstraZeneca, Harro Hoefliger, and ESSERT Robotics. GSK and AstraZeneca, both based in the UK, are leading pharmaceutical firms extensively integrating AI and automation technologies to accelerate drug discovery, development, and manufacturing processes, with GSK having established an AI hub in London for new drug discovery. Harro Hoefliger, a German company, specializes in flexible automation solutions for pharmaceutical production and packaging, offering machines for capsule, tablet, powder, and inhalation products and assembly carton packaging. ESSERT Robotics focuses on high-mix, low-volume automation, creating modular production lines tailored for pharmaceutical manufacturing and laboratory automation, emphasizing flexibility and variability in production output.
These companies leverage advancements such as AI-driven predictive maintenance, robotics, and digital transformation to enhance efficiency and maintain compliance in complex biopharma manufacturing environments. European pharmaceutical manufacturers, including these key players, are investing heavily in cybersecurity, AI, and physical automation to overcome challenges like data silos and regulatory audits. The increasing adoption of AI-powered virtual assistants and automation technologies optimizes operations, improving equipment effectiveness and productivity in the pharmaceutical supply chain across Europe. This collective innovation drives the growth and competitiveness of the biopharmaceutical automation market within the region.
Revenue Opportunities are defined by the measurements of Total Addressable Market (TOM) for the four largest market players, Serviceable Addressable Market (SAM), and Serviceable Obtainable Market (SOM). The measurements include both written analysis and current calculations for each company in the market for each country or region.
This report does not provide the names of companies in the market or written analysis of each market's trends within each country to provide a cost-effective report that focuses solely on the statistics and data on each market.
Wharry Sharpe Research publishes thousands of market analysis and product research report annually to assist their clients with the essential data they need for the market research, budgeting and forecasting needs.
Table of Contents
51 Pages
- A. Definitions
- A1. Market Definition
- A2. Market Segmentation
- A3. Industry Opportunities-Industry1
- A4. Industry Opportunities-Industry2
- A5. Industry Opportunities-Industry3
- B. Total Addressable Market (TAM)
- B1. TAM-Player 1/4
- B2. TAM-Player 2/4
- B3. TAM-Player 3/4
- B4. TAM-Player 4/4
- C. Serviceable Addressable Market (SAM)
- C1. SAM-Player 1/4
- C2. SAM-Player 2/4
- C3. SAM-Player 3/4
- C4. SAM-Player 4/4
- D. Serviceable Obtainable Market (SOM)
- D1. SOM-Player 1/4
- D2. SOM-Player 2/4
- D3. SOM-Player 3/4
- D4. SOM-Player 4/4
- E. Appendix
Search Inside Report
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
